References
- Abenavoli, L., et al., 2018. Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytotherapy research: PTR, 32 (11), 2202–2213.
- Araki, E., and Nishikawa, T., 2010. Oxidative stress: a cause and therapeutic target of diabetic complications. Journal of diabetes investigation, 1 (3), 90–96.
- Belviranli, M., et al., 2012. Oxidative stress and anti-oxidant status in diabetic rat liver: effect of plant polyphenols. Archives of physiology and biochemistry, 118 (5), 237–243.
- Brownlee, M., 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 414 (6865), 813–820.
- Cagel, M., et al., 2017. Mixed micelles for encapsulation of doxorubicin with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines versus Doxil®. Biomedicine & pharmacotherapy, 95, 894–903.
- Cole, J.B., and Florez, J.C., 2020. Genetics of diabetes mellitus and diabetes complications. Nature reviews nephrology, 16 (7), 377–390.
- Das, S., et al., 2014. Engineered silybin nanoparticles educe efficient control in experimental diabetes. PLOS one, 9 (7), e101818.
- di Costanzo, A., and Angelico, R., 2019. Formulation strategies for enhancing the bioavailability of silymarin: the state of the art. Molecules, 24 (11), 2155.
- El-Far, Y.M., et al., 2016. A newly developed silymarin nanoformulation as a potential antidiabetic agent in experimental diabetes. Nanomedicine, 11 (19), 2581–2602.
- El-Tantawy, W.H., et al., 2015. Investigation of antidiabetic action of Antidesma bunius extract in type 1 diabetes. Archives of physiology and biochemistry, 121 (3), 116–122.
- El-Tantawy, W.H., and Temraz, A., 2018. Management of diabetes using herbal extracts: review. Archives of physiology and biochemistry, 124 (5), 383–389.
- Gerber, P.A., and Rutter, G.A., 2017. The role of oxidative stress and hypoxia in pancreatic beta-cell dysfunction in diabetes mellitus. Antioxidants & redox signaling, 26 (10), 501–518.
- Glavas, M.M., et al., 2019. Early overnutrition reduces Pdx1 expression and induces β cell failure in Swiss Webster mice. Scientific reports, 9 (1), 3619.
- Javed, S., Kohli, K., and Ali, M., 2010. Patented bioavailability enhancement techniques of silymarin. Recent patents on drug delivery formula, 4 (2), 145–152.
- Jin, L., et al., 2008. Antioxidant and pancreas-protective effect of aucubin on rats with streptozotocin-induced diabetes. European journal of pharmacology, 582 (1–3), 162–167.
- Kazemi, M., et al., 2020. Deep skin wound healing potential of lavender essential oil and licorice extract in a nanoemulsion form: biochemical, histopathological and gene expression evidences. Journal of tissue viability, 29 (2), 116–124.
- Kheiripour, N., et al., 2019. Hepatoprotective effects of silymarin on liver injury via irisin upregulation and oxidative stress reduction in rats with type 2 diabetes. Iranian journal of medical sciences, 44, 108.
- Mohammadalipour, A., et al., 2017. Dasatinib prevent hepatic fibrosis induced by carbon tetrachloride (CCl4) via anti-inflammatory and antioxidant mechanism. Immunopharmacology and Immunotoxicology, 39 (1), 19–27.
- Oliveira, M.L.M., et al., 2020. Silymarin attenuates hepatic and pancreatic redox imbalance independent of glycemic regulation in the alloxan-induced diabetic rat model. Biomedical and Environmental Sciences, 33, 690–700.
- Özden, H., et al., 2005. Histopathologic examination of rat liver after experimental application of fluoxetine. Türkiye Ekopatoloji Dergisi, 11, 9–15.
- Park, S., et al., 2019. Recent advances in the pathogenesis of microvascular complications in diabetes. Archives of pharmacal research, 42 (3), 252–262.
- Piazzini, V., et al., 2019. Formulation of nanomicelles to improve the solubility and the oral absorption of silymarin. Molecules, 24 (9), 1688.
- Piazzini, V., et al., 2018. Nanostructured lipid carriers as promising delivery systems for plant extracts: the case of silymarin. Applied sciences, 8 (7), 1163.
- Sajedianfard, J., Behroozi, Z., and Nazifi, S., 2014. The effects of a hydroalcoholic extract of silymarin on serum lipids profiles in streptozotocin induced diabetic rats. Comparative clinical pathology, 23 (3), 779–784.
- Shakeel, F., et al., 2014. Measurement and correlation of solubility of bioactive compound silymarin in five different green solvents at 298.15 K to 333.15 K. Journal of molecular liquids, 195, 255–258.
- Smith, M.J., Simmons, K.M., and CAMBIER, J.C., 2017. B cells in type 1 diabetes mellitus and diabetic kidney disease. Nature reviews - nephrology, 13 (11), 712–720.
- Stolf, A.M., Cardoso, C.C., and Acco, A., 2017. Effects of silymarin on diabetes mellitus complications: a review. Phytotherapy research: PTR, 31 (3), 366–374.
- Tomita, T., 2017. Apoptosis of pancreatic β-cells in type 1 diabetes. Bosnian journal of basic medical sciences, 17 (3), 183–193.
- Voroneanu, L., et al., 2016. Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Journal of diabetes research, 2016, 5147468.
- Yu, H., et al., 2012. Epidermal growth factor and gastrin on PDX1 expression in experimental type 1 diabetic rats. American journal of medical sciences, 343 (2), 141–145.
- Zhang, J., Jasti, B., and Li, X., 2007. Formulation and characterization of silibinin-loaded sterically stabilized solid lipid nanoparticles. Drug delivery, 15, 381–387.